Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sillajen Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area, currently featuring 1 pending office action. This indicates a targeted prosecution phase for the company's biotech assets. The examination process is highly concentrated, involving 1 distinct examiner and 1 distinct art unit, which suggests that the company's current filings are focused on a specific technical domain.
The use of 1 distinct art unit ensures that the 1 pending office action is reviewed by a specialized group familiar with the relevant scientific area. For the practitioner, the 1 distinct examiner is the primary point of contact, making their individual examination style a critical factor. This concentration allows for a focused legal strategy that addresses the specific concerns of the 1 distinct art unit involved.
LY, KRISTINA ELISABETH is the busiest examiner for Sillajen Inc., currently overseeing 1 busiest examiner pending office action. This 1 action is the only pending matter in the portfolio, so the examiner's review will determine the immediate outcome of the company's patenting efforts. Addressing the 1 busiest examiner pending office action from LY, KRISTINA ELISABETH is the key priority for advancing the company's position in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, SEONG JONG | 1 | 20.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717567 | METHODS OF TREATING NEOPLASTIC DISEASES | KIM, SEONG JONG | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717567 | METHODS OF TREATING NEOPLASTIC DISEASES | KIM, SEONG JONG | 1621 | §103 | Final Rejection | — | Pending | Jun 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSillajen Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Seong Jong Kim has the most, with 1 of Sillajen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.